- Tags: geographic atrophy
Pipeline
Lineage reports positive 36-month findings on GA cell therapy
Results from the phase 1/2a trial of OpRegen demonstrate sustained BCVA and structural improvements.
Research
New IZERVAY findings link GA treatment to improved likelihood of retaining driving eligibility
Post hoc analysis demonstrates IZERVAY reduces risk of progressing to losing driving eligibility in GA patients.
Pipeline
Preliminary data evaluates Astellas's RPE cell therapy for advanced GA
Presented at ARVO 2026, early 26- and 52-week safety phase 1b data from highlights notable visual gains in patients receiving ASP7317.
Events
ARVO 2026 signals a turning point for retina innovations
Highlights from this year’s research in vision and ophthalmology meeting covered genetics, gene editing, AI, advanced imaging, and more.
Business
Biogen is purchasing Apellis
With an estimated price tag of $5.6 billion, the acquisition includes the FDA-approved SYFOVRE.
Pipeline
Complement Therapeutics begins patient dosing in GA gene therapy trial
Opti-GAIN trial is evaluating a single subretinal injection of CTx-001, an AAV-based gene therapy modulating multiple pathways of the complement system.
Research
Reducing chronic inflammation minimizes AMD-linked vision loss
Mouse model demonstrates role of NLRP3 in AMD pathology and highlights potential therapeutic approaches.
Research
Researchers develop clinical decision tool for GA treatment
Atrophy Advisor could help clinicians determine the optimal therapeutic approach for GA patients.
Pipeline
Complement Therapeutics secures Fast Track Designation for lead GA therapy
AAV-based CTx001 modulates multiple pathways of the complement system when delivered as a one-time, subretinal injection.
Pipeline
Aviceda releases phase 2b topline data on AVD-104 for GA
Latest SIGLEC trial results show both dosing arms with 31% to 38% less lesion growth than prior trials; phase 3 plans are underway.
Pipeline
SeaBeLife and Unither to formulate and develop retinal degenerative disorder formulation
Collaboration focuses on accelerating development of SBL03, formulated for topical delivery to target retinal cell necrosis in GA and dry AMD.
Research
New 5-year Syfovre data indicates extended delay of GA progression
GALE extension study findings show delayed GA lesion growth by an estimated 1.5 years in patients receiving continuous treatment.Pipeline
Complement Therapeutics' GA gene therapy IND receives FDA clearance
Clearance gives green light to begin Q1 2026 patient enrollment for the Opti-GAIN study evaluating CTx001 as a one-time, durable treatment.Research
Real-world data support IZERVAY's long-term benefits
OLE trial of the GATHER2 study finds continued GA lesion growth for up to 3.5 years—with earlier intervention offering greater protection of the retinal tissue.
Pipeline
FDA grants Sanofi Fast Track designation for GA gene therapy
Status gives expedited pathway toward regulatory approval for SAR446597, designed as a one-time injection that blocks two of the three complement system pathways.
Pipeline
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant
Also under clinical development for Stargardt disease, the once-daily tablet is under evaluation for its efficacy in slowing atrophic lesion growth.
Pipeline
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.Products
FDA approves updated label for IZERVAY to treat GA
Astellas’s avacincaptad pegol now has no limitation on its dosing duration, enabling longer-term administration for patients with GA secondary to AMD.
Business
Bausch + Lomb adds to glaucoma and GA pipeline with two deals
Latest developments involve the acquisition of WhiteCap Biosciences and its GA candidate, as well as a partnership with RNAi-focused City Therapeutics.Products